Pulmotect is a biotechnology company focused on developing innovative immunotherapy solutions to reduce complications in cancer patients undergoing chemotherapy and treat respiratory infections such as COPD and influenza. Operating in the immuno-stimulants market, Pulmotect targets immunocompromised patients who are at high risk of infections. The company’s core product, PUL-042, has shown promising results in Phase I clinical trials and is currently undergoing Phase II studies to assess its effectiveness in preventing respiratory tract complications. Pulmotect generates revenue through the development and commercialization of its proprietary immunotherapy treatments, aiming to address significant unmet medical needs in the healthcare industry. The company serves healthcare providers, hospitals, and patients, primarily in the United States, with potential for global market expansion.

Keywords: immunotherapy, cancer patients, respiratory infections, COPD, influenza, PUL-042, clinical trials, immuno-stimulants, biotechnology, healthcare.